Antibiotics Aren’t Profitable Enough for Big Pharma to Make More
10 May 2019
Public health experts are calling for new incentives to reward companies for bringing drugs that are effective against resistant strains to market.
Further reading: Bloomberg
Smart Innovations
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
